Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
21 Jun 2022
Historique:
received: 24 05 2022
revised: 15 06 2022
accepted: 16 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Somatostatin (also named as growth hormone-inhibiting hormone or somatotropin release-inhibiting factor) is a regulatory peptide important for the proper functioning of the endocrine system, local inflammatory reactions, mood and motor coordination, and behavioral responses to stress. Somatostatin exerts its effects via binding to G-protein-coupled somatostatin receptors of which the fourth subtype (SSTR4) is a particularly important receptor mediating analgesic, anti-inflammatory, and anti-depressant effects without endocrine actions. Thus, SSTR4 agonists are promising drug candidates. Although the knowledge of the atomic resolution-binding modes of SST would be essential for drug development, experimental elucidation of the structures of SSTR4 and its complexes is still awaiting. In the present study, structures of the somatostatin-SSTR4 complex were produced using an unbiased, blind docking approach. Beyond the static structures, the binding mechanism of SST was also elucidated in the explicit water molecular dynamics (MD) calculations, and key binding modes (external, intermediate, and internal) were distinguished. The most important residues on both receptor and SST sides were identified. An energetic comparison of SST binding to SSTR4 and 2 offered a residue-level explanation of receptor subtype selectivity. The calculated structures show good agreement with available experimental results and indicate that somatostatin binding is realized via prerequisite binding modes and an induced fit mechanism. The identified binding modes and the corresponding key residues provide useful information for future drug design targeting SSTR4.

Identifiants

pubmed: 35805885
pii: ijms23136878
doi: 10.3390/ijms23136878
pmc: PMC9266823
pii:
doi:

Substances chimiques

Analgesics 0
Receptors, Somatostatin 0
Somatostatin 51110-01-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Hungarian National Research, Development and Innovation Office
ID : K123836
Organisme : Hungarian National Research, Development and Innovation Office
ID : K134214
Organisme : National Research, Development and Innovation Fund of Hungary, financed under the EGA 16 funding scheme
ID : Project no. TKP2021-EGA-16
Organisme : National Research, Development and Innovation Fund of Hungary, financed under the EGA-13 funding scheme and Lorand Eotvos research Network
ID : Project no. TKP2021-EGA-13
Organisme : Hungarian Academy of Sciences
ID : János Bolyai Research Scholarship
Organisme : New National Excellence Program of the Ministry for Innovation and Technology
ID : ÚNKP-21-5
Organisme : New National Excellence Program of the Ministry for Innovation and Technology
ID : ÚNKP-21-3-II
Organisme : PTE ÁOK
ID : PTE ÁOK-KA 2021/KA-2021-39
Organisme : European Union, co-financed by the European Social Fund
ID : EFOP-3.6.1-16-2016-00004

Références

J Med Chem. 2003 Jul 3;46(14):2834-45
pubmed: 12825927
Int J Mol Sci. 2019 Sep 06;20(18):
pubmed: 31489952
Nucleic Acids Res. 2022 Jan 7;50(D1):D20-D26
pubmed: 34850941
Protein Sci. 2011 May;20(5):880-93
pubmed: 21413095
N Engl J Med. 1996 Jan 25;334(4):246-54
pubmed: 8532003
Pancreas. 2010 Nov;39(8):1155-66
pubmed: 20531241
Proteins. 2010 Jun;78(8):1950-8
pubmed: 20408171
Mol Divers. 2017 May;21(2):367-384
pubmed: 28155055
Front Endocrinol (Lausanne). 2021 Mar 16;12:652363
pubmed: 33796080
Nucleic Acids Res. 2022 Apr 12;:
pubmed: 35412617
J Biomol Struct Dyn. 2019 Aug;37(12):3081-3102
pubmed: 30079808
Hippocampus. 2010 Jun;20(6):745-57
pubmed: 19623609
Bioorg Med Chem. 2017 Nov 1;25(21):5995-6006
pubmed: 28988629
Mol Cell Endocrinol. 2008 May 14;286(1-2):199-205
pubmed: 18221833
Front Pharmacol. 2021 Jan 27;11:601887
pubmed: 33815096
Science. 1998 Oct 23;282(5389):737-40
pubmed: 9784130
J Med Chem. 1998 Nov 19;41(24):4693-705
pubmed: 9822540
Life (Basel). 2021 Oct 12;11(10):
pubmed: 34685446
Biochim Biophys Acta. 1982 Jan 18;700(2):229-46
pubmed: 6120006
J Chem Inf Model. 2012 Jan 23;52(1):171-86
pubmed: 22148589
J Neurochem. 2004 Jun;89(5):1057-91
pubmed: 15147500
Expert Rev Pharmacoecon Outcomes Res. 2019 Feb;19(1):15-25
pubmed: 30122081
Metabolism. 1996 Aug;45(8 Suppl 1):17-20
pubmed: 8769372
J Med Chem. 2003 Jun 5;46(12):2334-44
pubmed: 12773038
J Phys Chem B. 2012 Jun 21;116(24):7088-101
pubmed: 22612331
Ther Deliv. 2017 Oct;8(10):867-878
pubmed: 28944744
FEBS Lett. 1980 Jan 1;109(1):55-8
pubmed: 7353633
Life Sci. 1982 Sep 13;31(11):1133-40
pubmed: 6128648
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
EJNMMI Res. 2020 Aug 5;10(1):90
pubmed: 32757150
Biochem Biophys Res Commun. 1999 May 19;258(3):689-94
pubmed: 10329447
ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087
pubmed: 30429949
Best Pract Res Clin Gastroenterol. 2002 Jun;16(3):493-509
pubmed: 12079271
Mini Rev Med Chem. 2007 Mar;7(3):213-20
pubmed: 17346214
Nat Struct Mol Biol. 2022 Mar;29(3):210-217
pubmed: 35210615
Medchemcomm. 2018 Nov 7;9(12):2083-2090
pubmed: 30746066
FEBS Lett. 1980 Sep 22;119(1):47-52
pubmed: 6107249
Neuroendocrinology. 2016;103(1):50-8
pubmed: 25677539
Biomed Pept Proteins Nucleic Acids. 1995;1(3):109-16
pubmed: 9346841
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Curr Med Chem. 2017;24(39):4360-4367
pubmed: 28901275
Eur J Med Chem. 2019 Feb 1;163:148-159
pubmed: 30503939
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Eur J Pharmacol. 2011 Mar 1;654(1):53-9
pubmed: 21185826
Pharmacol Ther. 2015 Aug;152:98-110
pubmed: 25956467
Br J Pharmacol. 2006 Oct;149(4):405-15
pubmed: 16953190
Front Neuroendocrinol. 1999 Jul;20(3):157-98
pubmed: 10433861
Curr Drug Targets. 2016;17(5):529-37
pubmed: 26951062
Nature. 2016 May 04;533(7602):265-8
pubmed: 27144352
ACS Med Chem Lett. 2015 Jan 08;6(2):110-1
pubmed: 25699156
Neuropeptides. 2015 Feb;49:47-54
pubmed: 25599867
Mol Cell Endocrinol. 2007 Dec 15;279(1-2):34-8
pubmed: 17945410
Neuropharmacology. 2020 Nov 1;178:108198
pubmed: 32739276
Int J Mol Sci. 2019 Dec 11;20(24):
pubmed: 31835716
Biochem Biophys Res Commun. 1995 Nov 22;216(3):913-21
pubmed: 7488212
Curr Opin Struct Biol. 2021 Apr;67:1-8
pubmed: 32942197
Eur J Endocrinol. 2002 May;146(5):707-16
pubmed: 11980628
Biomedicines. 2022 Feb 01;10(2):
pubmed: 35203552
EMBO J. 1995 Feb 15;14(4):727-35
pubmed: 7882976
Proc Natl Acad Sci U S A. 1980 Nov;77(11):6827-31
pubmed: 6109284
Int J Mol Sci. 2019 Jan 19;20(2):
pubmed: 30669446
DNA Cell Biol. 1995 Nov;14(11):939-44
pubmed: 7576180
J Biol Chem. 1996 Aug 23;271(34):20331-9
pubmed: 8702767
Pharmacol Ther. 2006 Nov;112(2):440-56
pubmed: 16764934
Mol Pharmacol. 1997 Nov;52(5):807-14
pubmed: 9351971
Neuropharmacology. 2016 Feb;101:204-15
pubmed: 26387439
Eur J Pharmacol. 2015 Jan 5;746:274-81
pubmed: 25445035
Life Sci. 1984 Apr 2;34(14):1371-8
pubmed: 6143233
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234481
Phys Chem Chem Phys. 2018 Sep 19;20(36):23222-23232
pubmed: 30137066
Br J Pharmacol. 2001 Dec;134(7):1571-9
pubmed: 11724765
Endocrinology. 1994 Dec;135(6):2814-7
pubmed: 7988476
Protein Eng. 1991 Dec;4(8):903-10
pubmed: 1667878
Nature. 1981 Jul 2;292(5818):55-8
pubmed: 6116194
Biochem Biophys Res Commun. 2004 Apr 16;316(4):1059-64
pubmed: 15044092
Trends Pharmacol Sci. 1995 Mar;16(3):86-8
pubmed: 7792934
Int J Mol Sci. 2020 Oct 21;21(20):
pubmed: 33096776
J Cheminform. 2017 Dec 28;9(1):65
pubmed: 29282592
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Int J Mol Sci. 2019 Sep 27;20(19):
pubmed: 31569719
ACS Omega. 2020 Aug 11;5(33):21145-21161
pubmed: 32875251

Auteurs

Rita Börzsei (R)

Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, 7624 Pécs, Hungary.

Balázs Zoltán Zsidó (BZ)

Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, 7624 Pécs, Hungary.

Mónika Bálint (M)

Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, 7624 Pécs, Hungary.

Zsuzsanna Helyes (Z)

Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, 7624 Pécs, Hungary.
Algonist Gmbh, 1030 Vienna, Austria.
PharmInVivo Ltd., 7624 Pécs, Hungary.

Erika Pintér (E)

Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, 7624 Pécs, Hungary.
Algonist Gmbh, 1030 Vienna, Austria.
PharmInVivo Ltd., 7624 Pécs, Hungary.

Csaba Hetényi (C)

Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
János Szentágothai Research Centre & Centre for Neuroscience, University of Pécs, 7624 Pécs, Hungary.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin
1.00
Animals Mice Immunity, Innate Interneurons Synapses

Classifications MeSH